Terms: = Breast cancer AND PAM50 AND Clinical Outcome
14 results:
1. Caveolin-1 gene expression provides additional prognostic information combined with pam50 risk of recurrence (ROR) score in breast cancer.
Godina C; Belting M; Vallon-Christersson J; Isaksson K; Bosch A; Jernström H
Sci Rep; 2024 Mar; 14(1):6675. PubMed ID: 38509243
[TBL] [Abstract] [Full Text] [Related]
2. LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.
Cisneros-Villanueva M; Fonseca-Montaño MA; Ríos-Romero M; López-Camarillo C; Jiménez-Morales S; Langley E; Rosette-Rueda AS; Cedro-Tanda A; Hernández-Sotelo D; Hidalgo-Miranda A
Sci Rep; 2024 Jan; 14(1):1483. PubMed ID: 38233470
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Ancestry-specific Molecular and Survival Differences in Admixed Patients With breast cancer.
Telonis AG; Rodriguez DA; Spanheimer PM; Figueroa ME; Goel N
Ann Surg; 2024 May; 279(5):866-873. PubMed ID: 38073557
[TBL] [Abstract] [Full Text] [Related]
4. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
5. Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer.
Tamez-Peña JG; Rodriguez-Rojas JA; Gomez-Rueda H; Celaya-Padilla JM; Rivera-Prieto RA; Palacios-Corona R; Garza-Montemayor M; Cardona-Huerta S; Treviño V
PLoS One; 2018; 13(3):e0193871. PubMed ID: 29596496
[TBL] [Abstract] [Full Text] [Related]
6. Male breast cancer: correlation between immunohistochemical subtyping and pam50 intrinsic subtypes, and the subsequent clinical outcomes.
Sánchez-Muñoz A; Vicioso L; Santonja A; Álvarez M; Plata-Fernández Y; Miramón J; Zarcos I; Ramírez-Tortosa CL; Montes-Torres J; Jerez JM; de Luque V; Llácer C; Fernández-De Sousa CE; Pérez-Villa L; Alba E
Mod Pathol; 2018 Feb; 31(2):299-306. PubMed ID: 28984296
[TBL] [Abstract] [Full Text] [Related]
7. BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses.
Papadakis ES; Reeves T; Robson NH; Maishman T; Packham G; Cutress RI
Br J Cancer; 2017 Jun; 116(12):1585-1594. PubMed ID: 28510570
[TBL] [Abstract] [Full Text] [Related]
8. Portraying breast cancers with long noncoding RNAs.
Van Grembergen O; Bizet M; de Bony EJ; Calonne E; Putmans P; Brohée S; Olsen C; Guo M; Bontempi G; Sotiriou C; Defrance M; Fuks F
Sci Adv; 2016 Sep; 2(9):e1600220. PubMed ID: 27617288
[TBL] [Abstract] [Full Text] [Related]
9. Gene modules associated with breast cancer distant metastasis-free survival in the pam50 molecular subtypes.
Liu R; Zhang W; Liu ZQ; Zhou HH
Oncotarget; 2016 Apr; 7(16):21686-98. PubMed ID: 26934123
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract] [Full Text] [Related]
11. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
Magbanua MJ; Wolf DM; Yau C; Davis SE; Crothers J; Au A; Haqq CM; Livasy C; Rugo HS; ; Esserman L; Park JW; van 't Veer LJ
Breast Cancer Res; 2015 May; 17(1):73. PubMed ID: 26021444
[TBL] [Abstract] [Full Text] [Related]
12. Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Foukakis T; Lövrot J; Sandqvist P; Xie H; Lindström LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh J
Mol Oncol; 2015 Aug; 9(7):1384-91. PubMed ID: 25888067
[TBL] [Abstract] [Full Text] [Related]
13. Using multigene tests to select treatment for early-stage breast cancer.
Goncalves R; Bose R
J Natl Compr Canc Netw; 2013 Feb; 11(2):174-82; quiz 182. PubMed ID: 23411384
[TBL] [Abstract] [Full Text] [Related]
14. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
Azim HA; Michiels S; Zagouri F; Delaloge S; Filipits M; Namer M; Neven P; Symmans WF; Thompson A; André F; Loi S; Swanton C
Ann Oncol; 2013 Mar; 24(3):647-54. PubMed ID: 23337633
[TBL] [Abstract] [Full Text] [Related]
